Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) is the NASDAQ pre-market leader this morning on news that its subcutaneous SGI-110 interim phase I.II MDS and AML data demonstrated differentiated PK profile and good tolerability, as well as a preliminary promising complete responses in heavily pre-treated acute myelogenous leukemia patients enrolled in the Phase 1 segment of the trial.
The randomized Phase 1/2 first-in-human dose escalation study had 66 patients enrolled who were previously treated as of March 28, 2012.
In the data, two of the seven evaluable refractory AML patients with adequate hypomethylation with no prior resistance to hypomethylating agents showed a complete response and one patient showed partial response.
The pharmacokinetic data suggests delivery of decitabine by SGI-110 achieves high decitabine exposure. It also showed a longer half life and a potent dose-dependent hypomethylation induction in the daily regimen.
Shares are trading higher by 13.6% at $2.09 in the pre-market and the 52-week trading range is $1.51 to $3.35. The market cap before the news was a mere $171 million.
JON C. OGG
Credit card companies are handing out rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
